Castle Biosciences Inc

NASDAQ:CSTL  
65.48
-2.69 (-3.95%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.32B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$16.66 Million
Adjusted EPS-$0.24
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

Castle Biosciences, Inc. Stock, NASDAQ:CSTL

820 South Friendswood Drive, Suite 201, Friendswood, Texas 77546
United States of America
Phone: +1.866.788.9007
Number of Employees: 133

Description

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.